Huntington's disease is a genetic neurodegenerative disorder that affects both motor and cognitive function and gradually reduces the independence and quality of life of those affected. One of the ...

Healio spoke with Erin Furr Stimming, MD, about recent advancements and FDA approvals in Huntington’s disease.

Neurocrine's Ingrezza is expected to take a leading role in the treatment of chorea related to Huntington's disease. Read what this means for NBIX investors.

Treatment with valbenazine at doses up to 80 mg once daily was generally well-tolerated and significantly improved chorea compared with placebo in adults with Huntington’s disease, according to ...

Valbenazine is effective in improving symptoms of chorea for patients with Huntington's disease, without any increase in suicidal ideation or suicidal behavior, phase 3 trial results show.

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo.

Motor symptoms of Huntington's disease (HD) are so central to the genetic neurodegenerative disease that it was long called Huntington's chorea. However, they're often untreated, despite a growing ...

A new drug was approved for Huntington's chorea in 2023, and novel insights about Huntington's disease emerged in new research. Valbenazine for Huntington's Chorea In August, the FDA expanded the ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington’s disease, when compared to a placebo, according to a recent international study led ...

Nearly half of patients receiving Ingrezza saw a more than 40% reduction in Huntington disease chorea severity by the end of the treatment period.

A drug widely available in Europe and Canada – but not the United States – dramatically eases one of the most disabling symptoms of Huntington's disease, involuntary writhing movements known ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo, according to a recent international study led by ...